Results 71 to 80 of about 2,622 (185)

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Trials, 2023
Background Administration of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs has dramatically improved even the clinical outcomes in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate ...
Toshimasa Shimizu, Shin-ya Kawashiri, Shimpei Morimoto, Yurika Kawazoe, Shohei Kuroda, Rina Kawasaki, Yasuko Ito, Rieko Kiya, Shuntaro Sato, Hiroshi Yamamoto, Atsushi Kawakami   +10 more
doaj   +1 more source

Targeted therapy of inflammatory bowel diseases: realities and prospects

Медицинский совет, 2018
This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases.
I. V. Maev, D. N. Andreev
doaj   +1 more source

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Selective Drug‐Free Active Surveillance in Ulcerative Colitis: Biomarker‐Guided, Patient‐Centered Approach

JGH Open, Volume 10, Issue 4, April 2026.
ABSTRACT Ulcerative colitis (UC) is traditionally managed with long‐term 5‐aminosalicylic acid (5‐ASA) administration. However, in real‐world practice, carefully selected low‐risk patients in sustained deep remission may remain stable without continuous therapy.
Tsutomu Nishida, Naoto Osugi, Takahiro Amano, Takeo Yoshihara   +3 more
wiley   +1 more source

Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Tyrosine kinase inhibitors (TKIs) are essential in treating chronic myeloid leukaemia (CML) and other malignancies. Their absorption, however, is highly pH‐dependent, making them susceptible to interactions with acid‐suppressing agents such as proton pump inhibitors (PPIs), histamine‐2 receptor antagonists (H2RAs) and antacids ...
Marek Lapka, Anna Khryakova, Anastasiia Nazmutdinova, Chrysostomos Charalambous, Jan Bosak, Jiri Sliva   +5 more
wiley   +1 more source

Cholesterol Promotes Lung Adenocarcinoma Brain Metastasis by Stabilizing EGFR Protein to Drive EMT, Metabolic Reprogramming, and Premetastatic Niche Formation

Advanced Science, Volume 13, Issue 17, 23 March 2026.
Cholesterol is revealed as a multitasking fuel for lung adenocarcinoma brain metastasis: it locks EGFR at the membrane to sustain AKT/NF‐κB–driven glycolysis and EMT, loosens the blood–brain barrier by promoting Claudin‐5 loss, and rewires microglia through IL‐4R lipid‐raft–JAK1/STAT6 signaling.
Ying Chen, Xiaoteng Cui, Xinyi Shi, Xu Yang, Yujing Cao, Haolin LI, Qi Zhan, Qixue Wang, Ang Li, Qihong Cheng, Yunfei Wang, Junhu Zhou, MingJie Wang, Chunsheng Kang, Xiaomin Liu   +14 more
wiley   +1 more source

Unveiling the Potential of JAK Inhibitors in Inflammatory Bowel Disease

Biologics
Background: Janus kinase (JAK) inhibitors represent a novel class of oral therapies showing efficacy in treating ulcerative colitis (UC) and Crohn’s disease (CD), challenging conventional treatment paradigms.
Shahed Kamal, Sheng Wei Lo, Samantha McCall, Beverly Rodrigues, Andrew H. Tsoi, Jonathan P. Segal   +5 more
doaj   +1 more source

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study [PDF]

Intestinal Research
Background/Aims Real-world data on the use of filgotinib (FILGO) in patients with ulcerative colitis (UC) are limited. This study aims to provide consistent results on the effectiveness and safety of FILGO in treating UC.
Antonio Tursi, Giammarco Mocci, Francesco Costa, Linda Ceccarelli, Edoardo Savarino, Caterina De Barba, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Manuela Marzo, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Antonietta Gerarda Gravina, Raffaele Pellegrino, Rocco Spagnuolo, Francesco Luzza, Antonio Cuomo, Laura Donnarumma, Giovanni Maconi, Giovanni Cataletti, Lorenzo Bertani, Giorgia Bodini, Andrea Pasta, Simona Piergallini, Mariaelena Serio, Antonella Scarcelli, Pietro Capone, Fabio Cortellini, Stefano Rodino, Ladislava Sebkova, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Federica Gaiani, Stefano Kayali, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Antonio Ferronato, Davide Giuseppe Ribaldone, Giovanni Aragona, Patrizia Perazzo, Giacomo Forti, Michela Di Fonzo, Federico Iacopini, Roberta Pica, Claudio Cassieri, Francesca Maria Onidi, Paolo Usai Satta, Walter Elisei, Marcello Picchio, Alfredo Papa   +56 more
doaj   +1 more source

Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis

Rheumatology and Therapy
A Bayesian network meta-analysis was conducted to examine the radiographic and clinical efficacy of the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, upadacitinib, and filgotinib and the biologic disease-modifying antirheumatic drug (bDMARD ...
Yoshiya Tanaka, Rene Westhovens, Hong Sun, Carole Van der Donckt, Yan Zhong, Toshihiko Kaise   +5 more
doaj   +1 more source

Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence

Pharmaceuticals
Ulcerative colitis (UC) is an inflammatory bowel disease in which one-quarter of patients are at risk of developing a severe form of the disease known as acute severe UC (ASUC).
Raffaele Pellegrino, Giuseppe Imperio, Ilaria De Costanzo, Michele Izzo, Fabio Landa, Assunta Tambaro, Antonietta Gerarda Gravina, Alessandro Federico   +7 more
doaj   +1 more source